Description
LY3499446 is an experimental drug being studied by Eli Lilly and Company. It is currently in Phase 1 clinical trials for advanced solid tumors, including colorectal cancer, specifically in patients whose tumors have a KRAS G12C mutation. Phase 1 trials primarily focus on determining the safety and appropriate dosage of a new drug. The goal of the trial is to assess whether LY3499446 is safe and shows signs of effectiveness in patients with KRAS G12C-mutated tumors. This trial is part of the ongoing effort to develop new treatments for cancers driven by specific genetic mutations, like KRAS G12C.
Mechanism of Action
LY3499446 is being investigated as a potential treatment for cancers with a specific KRAS G12C mutation. KRAS is a gene that can mutate and contribute to cancer growth. The specific way LY3499446 works (its mechanism of action) is being studied in clinical trials. It is designed to target the effects of the KRAS G12C mutation in cancer cells.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.